Movement Alert｜Natera Falls 3.25% in Regular Trading, Recent Rally Shows Signs of Short-Term Pullback

Market Focus10-22

On October 22, Natera fell 3.25% in Regular Trading, trading at $398.03 per share, with turnover of $79.52 million.

The most recent market update indicates the move followed a period of strength driven by higher analyst price targets and product-related progress, while the latest weakness was characterized as a short-term pullback after that rally.

Earlier developments included Morgan Stanley raising its price target to $435 from $355 while maintaining an overweight rating, alongside progress in Natera’s multi-cancer early detection assay and Signatera commercialization. The company’s multi-cancer early detection assay received FDA Breakthrough Device Designation, and Signatera was approved in Japan as a companion diagnostic for muscle-invasive bladder cancer. Fundamentally, second-quarter revenue rose 37.7% year over year to $752.8 million, and full-year revenue guidance was lifted to $2.85 billion to $2.91 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment